Navigation Links
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results
Date:10/31/2011

PARSIPPANY, N.J., Oct. 31, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration's (FDA) approval of EXPAREL™ (bupivacaine liposome injectable suspension) and the commercial strategy to support the product launch.

"With the broad postsurgical pain management label granted by the FDA, we are well positioned to execute our commercial strategy for EXPAREL," said Dave Stack, president and chief executive officer of Pacira Pharmaceuticals, Inc. "Over the past several months, our entire organization has diligently focused on completing the pre-commercial activities necessary to prepare EXPAREL for launch. During this time, we have strengthened our relationships with clinicians and hospitals, presented data demonstrating the efficacy, safety and utility of EXPAREL and completed retrospective health outcomes studies highlighting the economic benefits of reducing opioid use in postsurgical pain management regimens. With these accomplishments as a platform, we believe we are on track for a successful hospital launch of EXPAREL in January 2012, focused on abdominal soft tissue surgeries typically performed by colorectal surgeons, general surgeons and OB/GYNs."

EXPAREL Commercial StrategyThe company has previously announced its intention to launch EXPAREL into the broad hospital market in early 2012.  By the time of launch, Pacira expects to have achieved the following:

  • Final analysis of its retrospective health outcomes research studies, which demonstrate that in certain patient populations, opioid-based pain management often leads to patient care and economic challenges. The first of these data sets will be presented at the American Society of Health
    '/>"/>

  • SOURCE Pacira Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
    2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
    3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
    4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPARELâ„¢ New Drug Application for Pain Management
    5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
    6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
    7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPARELâ„¢ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
    8. Pacira Pharmaceuticals EXPARELâ„¢ Data to be Featured at 2011 ASCPT 112th Annual Meeting
    9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
    10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
    11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
    (Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
    (Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
    Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
    (Date:4/17/2014)... of chronic inflammation in non-cancerous prostate tissue may have ... than those with no inflammation, according to results of ... Hopkins Kimmel Cancer Center. , The link between persistent ... so-called high-grade prostate cancer those with a Gleason ... of the most aggressive and rapidly growing prostate cancers. ...
    (Date:4/17/2014)... new pain relief targets that could be used ... at King,s College London made the discovery when ... periphery of the body. , Dr Marzia Malcangio ... underlying pain generation and our findings could help ... , One potential side effect of some chemotherapy ...
    (Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
    (Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
    (Date:4/17/2014)... review published in the April issue of Immunity ... Institute for Medical Research, says it,s time to take ... to treating sepsis, which kills millions worldwide every ... when molecules released into the bloodstream to fight an ... is necessary for maintaining good health without inflammation, ...
    Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
    ... 29, 2007 Traditionally, clinicians have relied on ... visits as the primary means of assessing patients ... could arise if important symptoms go unreported during ... A new study by researchers at Memorial Sloan-Kettering ...
    ... Nov. 29 Today, the Infectious,Diseases Institute (IDI) ... leader in HIV/AIDS prevention and treatment, as the ... joining IDI, Dr. Coutinho spent six years leading ... care and treatment,organization in Africa. His impressive accomplishments ...
    ... New MEDEX Global Group/Harvard Medical International Website goes beyond, ... the Lesser-Known Factors ... Healthcare, BALTIMORE, Nov. 29 Determining health risks ... incredibly complex.,According to the just published MEDEX 360m International ...
    ... Nov. 29 AtriCure, Inc.,(Nasdaq: ATRC ), a ... announced today that David J. Drachman, President and,Chief Executive ... Markets,2007 Healthcare Conference at the Millennium Broadway Hotel in ... ET., A live web cast and recording of ...
    ... 29 Specialty chemicals,maker Albemarle Corporation (NYSE: ... (also referred to as DBM, methylene dibromide, or,MDB) ... 2007, or as contracts allow., (Logo: ... needed to cover higher costs, in particular,higher raw ...
    ... on seizures linked to lamotrigine use, research shows , ... levels of the drug lamotrigine in pregnant women with epilepsy ... research shows. , Lamotrigine, an epilepsy drug, is taken by ... of causing birth defects. However, the drug has also been ...
    Cached Medicine News:Health News:Cancer patients may benefit from reporting symptoms online in real time 2Health News:Cancer patients may benefit from reporting symptoms online in real time 3Health News:Cancer patients may benefit from reporting symptoms online in real time 4Health News:Infectious Diseases Institute Appoints Alex Coutinho, M.D as Executive Director 2Health News:Infectious Diseases Institute Appoints Alex Coutinho, M.D as Executive Director 3Health News:MEDEX 360m Rates the State of Global Medical Care for Travelers 2Health News:AtriCure to Present at BMO Capital Markets 2007 Healthcare Conference 2Health News:Albemarle to Raise Prices of Dibromomethane 2Health News:Tracking Drug Levels Helps Pregnant Women With Epilepsy 2
    ... Cardiovascular Patch utilizes advanced fluoropolymer ... around penetrating suture and decrease ... much as 88 percent. This ... retention, multi-directional strength and low ...
    ... surgery, modified Blalock-Taussig shunts provide palliation of ... GORE-TEX Vascular Grafts configured for Pediatric Shunts ... use as shunts in pediatric cardiac procedures. ... ease of implantation and take-down at total ...
    ... techniques for vascular surgery, and the accompanying ... specialized types of graft be developed. Grafts ... biocompatible, but also available in varying sizes ... Vascular Graft has long been the prosthetic ...
    ... have met the challenges of the most ... Recognized for exceptional performance and quality, they ... worldwide. These grafts require no preclotting, resist ... assure utmost thrombectomy safety. Gore vascular grafts ...
    Medicine Products: